Cadrenal Therape SEC Filings

Cadrenal Therapeutics (CVKD) filed a Form 144 notifying a proposed sale of 100 common shares through Morgan Stanley Smith Barney with an aggregate market value of $1,403, scheduled approximately for 09/29/2025. The filing reports total shares outstanding of 2,046,854, and shows the 100 shares were acquired as founders shares on 05/17/2022. The filer represents compliance with Rule 144 and states no undisclosed material adverse information. The filing also lists recent Rule 10b5-1 sales by Matthew Szot totaling 14,400 shares between 08/27/2025 and 09/25/2025 for gross proceeds of $179,166.01.

Cadrenal Therapeutics, Inc. (CVKD) filing is a Form 144/A notice reporting a proposed sale of 6,790 common shares through Merrill Lynch (Ponte Vedra Beach, FL) with an approximate aggregate market value of $95,661.94, and an approximate sale date of 09/25/2025 on NASDAQ. The shares were acquired as Founders Shares on 01/25/2022. The filing also discloses three insider sales in the past three months by Quang X. Pham totaling 7,610 shares for gross proceeds of $106,104.20 across sales on 08/27/2025, 08/28/2025, and 09/24/2025. The notice includes the required certification that the seller is not aware of undisclosed material adverse information.

Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, Inc. (CVKD), reported sales of company common stock on two dates. On 09/24/2025 he sold 1,500 shares at a weighted average price of $13.9953, and on 09/25/2025 he sold 10,900 shares at a weighted average price of $14.0534, for a total of 12,400 shares sold. After these transactions the reporting person beneficially owned 18,933 shares, down from 29,833 shares following the first sale. The Form 4 is signed by the reporting person on 09/26/2025 and includes explanatory notes that the reported sales occurred in multiple transactions within the stated price ranges.

Cadrenal Therapeutics insider Form 4 summary: Quang Pham, CEO, Chairman, director and reported 10% owner of Cadrenal Therapeutics, Inc. (CVKD), reported sales of company common stock on 09/24/2025 and 09/25/2025. On 09/24/2025 he sold 2,581 shares at $13.99 each, leaving 210,723 shares directly owned after that transaction. On 09/25/2025 he sold 6,790 shares in multiple transactions with a weighted average price of $14.09, leaving 203,933 shares directly owned after those sales. Mr. Pham also has indirect ownership of 200,000 shares held by The PVBQ Living Trust; he is Trustee with sole voting and disposition power and the trust’s sole beneficiary is his child. The filing was signed by an attorney-in-fact on 09/26/2025.

Form 144 filed for Cadrenal Therapeutics, Inc. (CVKD) reporting proposed and recent insider sales. The notice shows a proposed sale of 6,790 common shares through Merrill Lynch (Ponte Vedra Beach, FL) with an aggregate market value of $95,661.94 and an approximate sale date of 09/24/2025 on NASDAQ. The shares were acquired as Founders Shares on 01/25/2022 from the issuer. The filing also discloses sales by Quang X. Pham during the past three months: 3,836 shares on 08/27/2025 (gross proceeds $53,455.56), 1,193 shares on 08/28/2025 (gross proceeds $16,540.64), and 2,581 shares on 09/24/2025 (gross proceeds $36,108), totaling $106,104.20 in gross proceeds.

Form 144 notice for Cadrenal Therapeutics, Inc. (CVKD) reports a proposed sale of 10,900 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $150,202 and an approximate sale date of 09/25/2025 on NASDAQ. The shares were acquired as founders' shares on 05/17/2022 from the issuer and the filer indicates payment was made on that date.

The filing also discloses three recent 10b5-1 sales by Matthew Szot totaling 3,500 shares for gross proceeds of $48,984.95, with trades dated 08/27/2025, 08/28/2025 and 09/24/2025. The filer certifies no undisclosed material adverse information and references a trading plan where applicable.

Form 144 notice for proposed sale of securities (Rule 144) filed for common stock to be sold on 09/24/2025 on NASDAQ. The notice lists 2,581 shares to be sold with an aggregate market value of $36,108 against 2,046,854 shares outstanding. The shares were acquired as Founders Shares on 01/25/2022. Recent sales by the same person are disclosed: 3,836 shares sold on 08/27/2025 for $53,455.56 and 1,193 shares sold on 08/28/2025 for $16,540.64. The filing includes a seller representation about absence of undisclosed material adverse information. Several issuer and filer identification fields in the form are blank or not provided in the supplied content.

Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 notifying the proposed sale of 1,500 common shares through Morgan Stanley Smith Barney on 09/24/2025 with an aggregate market value of $20,520 and 2,046,854 shares outstanding. The shares were acquired as Founders Shares on 05/17/2022. The filing also discloses recent 10b5-1 sales by the same account on 08/27/2025 (1,600 shares, $22,392) and 08/28/2025 (400 shares, $5,600). The filer certifies no undisclosed material adverse information and indicates reliance on established trading procedures where applicable.

Cadrenal Therapeutics, Inc. reported the outcome of its auditor ratification vote on September 24, 2025. The company disclosed vote totals for the Auditor Ratification Proposal showing 1,207,152 votes in favor, 64,913 votes against, 12,681 abstentions and 0 broker non‑votes. The filing lists Steven Zelenkofske and is signed by Quang X. Pham, Chairman and Chief Executive Officer. This item records a routine corporate governance vote approving the company's independent auditor; no financial results, material transactions, or other operational details were included in the provided text.